- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03038230
MCLA-117 in Acute Myelogenous Leukemia
A Phase 1, Multinational Study of MCLA-117 in Acute Myelogenous Leukemia
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Design :
This open label, single arm, multinational, first-in-human study consists of 2 parts. Part 1 consists of dose escalation cohorts and Part 2 is a dose expansion cohort.
The study population will include adult AML patients (and all subtypes of AML, except for APL) with relapse or refractory disease and newly diagnosed elderly untreated AML patients with high risk cytogenetics. In addition, very high-risk MDS patients with relapsed or refractory disease are eligible.
In Part 1, dose escalations cohorts are followed until dose-limiting toxicity (DLT) or a maximum tolerated dose (MTD) or RecommendedPart2Dose (RP2D) is defined. Dose escalation decisions will be made by the Data Review Committee and will be primarily guided by safety data observed through the end of Cycle 1, as well as on-going assessment of safety beyond Cycle 1 in later cohorts.
Part 2 will begin once the MTD or RP2D is determined in Part 1. Part 2 will further characterize the safety, tolerability, Pharmacokinetic (PK), Pharmacodynamic (PD), immunogenicity and to assess preliminary efficacy of MCLA-117. This part will enroll approximately 30 evaluable patients (defined as evaluable for first efficacy assessment).
For both parts, the study consists of 3 periods: a Screening period (up to 28 days prior to the first dose of study drug); a Treatment period (first dose of study drug until the last dose of study drug with treatment cycles of 28 days); and a Follow Up period (through 30 days after the last dose and quarterly checks for survival data for up to 1 year). Participants' safety will be monitored throughout the study. Patients will be permitted to receive MCLA-117 beyond Cycle 1 if conditions allow this.
Number of Sites:
Approximately 15 centers in five countries are estimated to be involved during Parts 1 and 2 of the study. Additional sites may be added to ensure there is an acceptable enrollment rate or to replace non-enrolling/withdrawn sites.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Antwerpen, Belgium, 2060
- Ziekenhuis Netwerk Antwerpen Campus Stuivenberg
-
-
-
-
Ile-de-France
-
Villejuif Cedex, Ile-de-France, France, 94805
- Institut Gustave Roussy
-
-
-
-
-
Rome, Italy, 00133
- Fondazione Policlinico Tor Vergata
-
-
-
-
-
Groningen, Netherlands
- Universitair Medisch Centrum Groningen
-
-
Noord-Holland
-
Amsterdam, Noord-Holland, Netherlands, 1081HV
- Amsterdam UMC, location VUmc
-
-
Zuid-Holland
-
Rotterdam, Zuid-Holland, Netherlands
- Erasmus MC
-
-
-
-
Georgia
-
Augusta, Georgia, United States, 30912
- Georgia Cancer Center, Augusta University
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Dana Farber Cancer Institute
-
-
New York
-
New York, New York, United States, 10029
- Icahn School of Medicine at Mount Sinai
-
-
Texas
-
Houston, Texas, United States, 77030
- The University of Texas, MD Anderson Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female age ≥18 years old;
- Signed informed consent form
One of the two following:
i) AML either de novo or secondary [any subtype except acute promyelocytic leukemia (APL)] who either:
- are in relapse to standard therapy following an initial response
- failed primary induction therapy with no CR (failed ≥2 courses of intensive induction therapy. Intensive chemotherapy defined as an intensity of ≥ 5+2)
- newly diagnosed untreated AML in patients ≥ 65 years of age with high risk cytogenetics, if they are not candidates for standard available induction chemotherapy
- AML secondary to MDS, either relapsed or refractory, previously treated with hypomethylating agents for at least 4 cycles;
- Relapsed or refractory AML unfit for intensive chemotherapy previously treated with a low intensity regimen (e.g. low dose Ara-c, hypomethylating agent, etc.) including Venetoclax for at least 2 cycles;
OR ii) MDS patients who meet the following criteria: very high-risk disease (IPSS-R score > 6, Greenberg et al., 2012), either relapsed or refractory, previously treated with hypomethylating agents for at least 4 cycles;
- Must have baseline BM sample taken by BMA/BMB within 28 days prior to first dose of MCLA-117 for CLEC12A detection;
- Estimated life expectancy of at least 8 weeks;
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2;
- Significant toxicities incurred as a result of previous anti-cancer therapy resolved to ≤ Grade 1 (NCI-CTCAE version 4.03);
- Acceptable laboratory values at screening;
- Male patients must agree to use an adequate and medically accepted method of contraception throughout the study and for at least 6 months after if their sexual partners are women of child bearing potential (WOCBP).
- WOCBP must be using highly effective and medically accepted method of contraception to avoid pregnancy throughout the study and for at least 6 months after the study ;
- WOCBP must have a negative serum or urine pregnancy test within 72 hours prior to the start of study drug.
- Peripheral blast count </= 30,000/mm3 at the time of initiation of infusion on Cycle 1 Day 1.
- Able and willing to comply with all study procedures.
Exclusion Criteria:
- Diagnosis of chronic myelogenous leukemia in blast crisis;
- Prior hematopoietic stem cell transplantation (this exclusion applies for dose escalation Part 1 and Cohort A of Part 2);
- For patients in Cohort B of Part 2, prior hematopoietic stem cell transplantation is allowed under certain circumstances.
- Treatment with anticancer medications, investigational drugs or radiotherapy is allowed within 2 weeks or 5 half-lives prior to start of MCLA-117;
- Previous receipt of live vaccines in the 4 weeks prior to study drug administration;
- Chronic concurrent need of use of corticosteroids > 10 mg/day of oral prednisone or the equivalent, except topical preparations (e.g., topical creams, steroid inhaler, nasal spray or ophthalmic solution);
- Use of immunosuppressant medications within 4 weeks of MCLA-117 administration;
- Clinically active central nervous system (CNS) leukemia;
- Patients who are pregnant or lactating;
- Patients with an active infection or with an unexplained fever during screening or on the first scheduled day of dosing;
- Patients with known hypersensitivity to any of the components of MCLA-117 or who have had prior hypersensitivity reactions to human or humanized monoclonal antibodies;
- Patients with known HIV, hepatitis B or C;
- Patients with New York Heart Association Class III or IV congestive heart failure or left ventricular ejection fraction (LVEF) < 50%, or significant uncontrolled cardiac disease, current diagnosis of unstable angina, uncontrolled congestive heart failure, new myocardial infarction, or ventricular arrhythmia requiring medication;
- Prior malignancy (other than basal cell carcinoma and cervical in situ carcinoma) unless treated with a curative intend and without evidence of malignant disease for 1 year before screening. Patients with prior hematologic malignancies that have progressed to AML (such as Myelodysplastic syndrome, myeloproliferative neoplasms, bi-phenotypic leukemias, AcuteLymphocyticLeukemia) or AML that has relapsed are eligible;
- Urinary protein >2+ possibly indicative of renal disease. If the 24 hours urine protein shows a result of < 100 mg protein, subject can be eligible;
- Patients with any other medical or psychological condition deemed by the Investigator to be likely to interfere with a patient's ability to sign informed consent, cooperate and participate in the study, or interfere with the interpretation of the results;
- WOCBP or males with a WOCB partners not willing to use highly effective and medically accepted methods of contraception for 6 months after last study drug administration.
- Need for concurrent other cytoreductive chemotherapy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MCLA-117 bispecific antibody
Dose escalation cohorts, with escalating doses of MCLA-117 until MTD or RP2D is reached. The dose is given weekly after initial ramp-up dosing steps. Each Cycle is 28 days. Single agent treatment. Part 2-Expansion Cohort: The RP2D of MCLA-117 is given weekly after initial ramp-up dosing steps. Each Cycle is 28 days. Single agent treatment. |
MCLA-117, a human bispecific IgG antibody which targets CLEC12A and CD3
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with Dose Limiting Toxicities (DLT)
Time Frame: 28 days
|
Evaluation of number of participants with treatment related toxicity observed during a dose escalation step for 1 Cycle
|
28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum plasma concentration [Cmax]
Time Frame: Day 22 predose, 5 minutes prior to End of Infusion (EOI), 1h, 2h, 4h, 8h, 24h, 72h, 6 days after EOI
|
Maximum plasma concentration [Cmax] as measured from all individual plasma concentrations
|
Day 22 predose, 5 minutes prior to End of Infusion (EOI), 1h, 2h, 4h, 8h, 24h, 72h, 6 days after EOI
|
Clearance of plasma
Time Frame: Day 22 predose, 5 minutes prior to End of Infusion (EOI), 1h, 2h, 4h, 8h, 24h, 72h, 6 days after EOI
|
Clearance of plasma
|
Day 22 predose, 5 minutes prior to End of Infusion (EOI), 1h, 2h, 4h, 8h, 24h, 72h, 6 days after EOI
|
Volume of distribution at steady state [Vss]
Time Frame: Day 22 predose, 5 minutes prior to End of Infusion (EOI), 1h, 2h, 4h, 8h, 24h, 72h, 6 days after EOI
|
Volume of distribution at steady state [Vss]
|
Day 22 predose, 5 minutes prior to End of Infusion (EOI), 1h, 2h, 4h, 8h, 24h, 72h, 6 days after EOI
|
Time to reach maximum plasma concentration [Tmax]
Time Frame: Day 22 predose, 5 minutes prior to End of Infusion (EOI), 1h, 2h, 4h, 8h, 24h, 72h, 6 days after EOI
|
Time to reach maximum plasma concentration [Tmax]
|
Day 22 predose, 5 minutes prior to End of Infusion (EOI), 1h, 2h, 4h, 8h, 24h, 72h, 6 days after EOI
|
Half-life [t1/2]
Time Frame: Day 22 predose, 5 minutes prior to End of Infusion (EOI), 1h, 2h, 4h, 8h, 24h, 72h, 6 days after EOI
|
Half-life [t1/2] calculated as time from all individual plasma concentrations to reach 50% of maximum concentration
|
Day 22 predose, 5 minutes prior to End of Infusion (EOI), 1h, 2h, 4h, 8h, 24h, 72h, 6 days after EOI
|
Area under the concentration versus time curve from time zero to time t [AUC0-t]
Time Frame: 1 week
|
Area under the concentration versus time curve [AUC0-t]
|
1 week
|
Incidence of AntiDrugAntibodies (ADA) against MCLA-117
Time Frame: 24 months
|
Number of participants with ADAs against MCLA-117 as measured in serum
|
24 months
|
Serum titer of ADAs against MCLA-117
Time Frame: Day 1 of each cycle
|
Serum titer of ADAs against MCLA-117 as measured in serum
|
Day 1 of each cycle
|
Serum titer of ADAs against MCLA-117
Time Frame: Day 28 of each cycle
|
Serum titer of ADAs against MCLA-117 as measured in serum
|
Day 28 of each cycle
|
Cytokine levels
Time Frame: Cycle 1: Day 1, 4, 8 and 28 at predose, 4h and 24h after end of infusion
|
Change in profile of cytokine upon administration of MCLA-117 compared to baseline
|
Cycle 1: Day 1, 4, 8 and 28 at predose, 4h and 24h after end of infusion
|
Number of myeloblasts
Time Frame: Day 1 of every cycle and through study completion, an average of 2 months
|
number of blasts in peripheral blood and in bone marrow
|
Day 1 of every cycle and through study completion, an average of 2 months
|
Objective response
Time Frame: Day 1 of every cycle and through study completion, an average of 2 months
|
Objective response is assessed by Cheson 2003
|
Day 1 of every cycle and through study completion, an average of 2 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jorge Cortes, MD, PhD, Independent Protocol Advisor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- MCLA-117-CL01
- 2015-003704-23 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Myeloid Leukemia
-
University of PennsylvaniaActive, not recruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia, Refractory | Acute Myeloid Leukemia, PediatricUnited States
-
National Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
Terrence J Bradley, MDImago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New...RecruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in RelapseUnited States
-
Bhavana BhatnagarCTI BioPharmaCompletedRecurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
Jacqueline Garcia, MDEli Lilly and CompanyCompletedCombination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid LeukemiaRelapsed Adult Acute Myeloid Leukemia | Refractory Adult Acute Myeloid LeukemiaUnited States
-
University of NebraskaNational Cancer Institute (NCI)Active, not recruitingSecondary Acute Myeloid Leukemia | Therapy-Related Acute Myeloid Leukemia | Adult Acute Myeloid LeukemiaUnited States
-
Massachusetts General HospitalExelixisCompletedRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
Washington University School of MedicineWithdrawnRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
C. Babis AndreadisGateway for Cancer Research; AVEO Pharmaceuticals, Inc.TerminatedAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
Clinical Trials on MCLA-117 bispecific antibody
-
Merus N.V.Incyte CorporationRecruitingAdvanced Cancer | Solid Tumor, Adult | B-cell Lymphoma, AdultUnited States, Spain, Belgium, Netherlands
-
Merus N.V.RecruitingNSCLC Harboring NRG1 Fusion | Solid Tumours Harboring NRG1 Fusion | Pancreatic Cancer Harboring NRG1 Fusion | NRG1 FusionSpain, France, Israel, Belgium, Denmark, United States, Korea, Republic of, Japan, Germany, Netherlands, Austria, Canada, Italy, Norway, Singapore, Sweden, Taiwan, United Kingdom
-
Y-mAbs TherapeuticsTerminatedOsteosarcoma | Neuroblastoma | Other Solid Tumor CancersUnited States
-
OncoMed Pharmaceuticals, Inc.CompletedAdvanced Solid Tumor MalignanciesUnited States
-
Nanfang Hospital, Southern Medical UniversityNot yet recruitingAdvanced Solid TumorsChina
-
Merus N.V.RecruitingGastric Cancer | Head and Neck Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma | Non-Small Cell Lung Cancer MetastaticUnited States, Spain, France, Italy, Netherlands, Belgium, Korea, Republic of, Germany, Singapore
-
OncoMed Pharmaceuticals, Inc.TerminatedMetastatic Colorectal CancerUnited States
-
Abramson Cancer Center at Penn MedicineXencor, Inc.Active, not recruiting
-
Xiangya Hospital of Central South UniversityActive, not recruiting
-
Dartmouth-Hitchcock Medical CenterNational Cancer Institute (NCI)TerminatedLymphoma | LeukemiaUnited States